Session Details
[2AS-10]【E】Beyond CAR-T: Pioneering New Horizons in Designer Cell Technology
Thu. Dec 4, 2025 9:00 AM - 11:00 AM JST
Thu. Dec 4, 2025 12:00 AM - 2:00 AM UTC
Thu. Dec 4, 2025 12:00 AM - 2:00 AM UTC
Room 10(Pacifico Yokohama Conference Center 4F, 413)
Organizer: Hideshi Ishii (The University of Osaka), Tomoaki Hara (The University of Osaka)
Chimeric Antigen Receptor (CAR) T-cell therapy is a groundbreaking technology that endows cells with new functionalities, bridging the fields of regenerative medicine and gene therapy to treat a variety of diseases. While regulatory authority-approved CAR-T therapies have shown dramatic effects, several challenges remain. This symposium will build upon the successes of CAR-T therapy, focusing on advancements in cell targeting techniques and the development of novel vectors. We will share and discuss the latest insights for clinical applications of next-generation technologies, aiming to accelerate the translation of molecular biology innovations into medical practice.
[2AS-10-01]Engineered CAR-macrophages for immune cell therapies
○JIN ZHANG1 (1. Zhejiang University)
[2AS-10-02]Improvement of CAR-T cell manufacturing method to enhance antitumor efficacy against solid cancer
○Yukimi Sakoda1 (1. Yamaguchi University Graduate School of Medicine)
[2AS-10-03]mRNA-LNP-based programmable platform to rewire immunity against solid tumors
○SIKUN MENG1, Tomoaki Hara1, Shotaro Tatekawa2, Tetsuya Sato3, Yoshiko Saito1, Yasuko Arao1, Taroh Satoh4, Hidetoshi Eguchi4, Kazuhiko Ogawa2, Yutaka Miura5, Hideshi Ishii1 (1. Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, 2. Department of Radiation Oncology, Osaka University Graduate School of Medicine, 3. Biomedical Research Center, Faculty of Medicine, Saitama Medical University, 4. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 5. Laboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo)
[2AS-10-04(2P-277)]Development of a designer cell elimination system using plant hormone.
○Satoshi Yoshimoto1, Zhuohao Yang2, Yoshitaka Shirasaki2, Satoshi Yotsumoto3, Kosuke Dodo1 (1. RIKEN, 2. University of Tokyo, 3. Tokyo University of Pharmacy and Life Sciences)
[2AS-10-05]Development of in vitro T-cell differentiation culture system from human iPS cells for “off-the-shelf” CAR-T cell products
○Shoichi Iriguchi1 (1. Kyoto University)
[2AS-10-06]Development of iPSC derived GD2 targeted chimeric antigen receptor T cell therapy for GD2 positive tumors
○Shintaro Kinoshita1, Midori Ishii1, Norihide Izumi1, Jun Ando1, Miki Ando1 (1. Department of hematology, Juntendo University)
[2AS-10-07]Identification of Therapeutic Target Antigens using patient derived glioblastoma and their clinical application to CAR-T cell therapy against glioblastoma
○Noriyuki Kijima Kijima1, Tetsuro Tachi1, Hideki Kuroda1, Shunya Ikeda2, Tomoyoshi Nakagawa1, Kanji Nakagawa1, Yuki Wada1, Tatsuya Hagioka1, Naoko Hatanaka1, Haruhiko Kishima1, Naoki Hosen2 (1. Dep.Neurosurgery, The University of Osaka, Graduate School of Medicine, 2. Dep.Hematology and Oncology, The University of Osaka, Graduate School of Medicine)
[2AS-10-08]CXCR4 expression promotes memory differentiation and oxidative metabolism of CAR-T cells, enhancing AML therapy in the hypoxic bone marrow
○Ari Itoh-Nakadai1, Fumihiko Ishikawa2 (1. Dep. Hygiene & Public Health, NMS, 2. Dep. Comprehensive Pathology, Med. & Dent. Sci., Institute of Science Tokyo)